567. Estimates of the Indirect Burden of Invasive Meningococcal Disease: Insight from Public Health Officials
Session: Poster Session: Hospital-acquired and Transplant Infections
Friday, October 30, 2009: 12:00 AM
Room: Poster Hall A
Background: Invasive Meningococcal disease (IMD) occurs in 1,400-3,000 persons in the US each year. While most cases are sporadic, outbreaks can occur, especially in young children and people living in close quarters (e.g., college students), making the disease a significant public health (PH) concern. The total economic burden of IMD includes more than direct costs incurred by affected individuals (e.g., productivity losses; costs associated with preventing an outbreak). These costs are not available in administrative databases but may be estimated using information available to PH experts. The objective of this study was to assess the indirect economic burden of IMD from a PH perspective.
Methods: PH officials from US states with the greatest number of incident cases of IMD were asked to participate in a brief electronic survey. Data sought included usual course of care for incident cases, measures taken to mitigate further outbreak, and provision of prophylactic care. Indirect cost component data such as cost of PH personnel time and productivity losses of affected individuals (i.e., number of sick days) were also gathered.
Results: PH officials from 367 counties were contacted, with participation from officials in 22 counties. On average, 15 people were provided prophylactic antibiotics and ~4 people were provided prophylactic vaccine for each IMD case. For children (≤18 years), Rifampin was the prophylactic drug most likely to be prescribed, and adults (19-25 years) were mostly prescribed Ciprofloxacin. The mean prescription length for Rifampin was 2.4 days and for Ciprofloxacin, 1 day. On average, patients required ~9 days to resume normal activities. The cost of PH personnel time needed to manage a case varied widely, ranging from $100-$9,000.
Conclusion: Increased awareness of IMD is needed in light of its burden. Efforts to collect reliable data across the entire spectrum of care are important undertakings. This study sought to quantify components of the indirect economic burden of IMD using data provided by PH officials. The results presented here may be used to derive a more complete estimate of the total economic burden of IMD.
Bela Bapat, MA, RTI Health Solutions, Timothy Bell, MSPH, GlaxoSmithKline, Sean Candrilli, PhD, RTI Health Solutions, Research Triangle Park, NC and  B. Bapat,
GlaxoSmithKline Role(s): Research Contractor, Received: Consulting Fee.
T. J. Bell,
GlaxoSmithKline Role(s): Employee, Received: Salary.
S. D. Candrilli,
GlaxoSmithKline Role(s): Research Contractor, Received: Consulting Fee.